READOUT // 08 — ABOUT
About MOTS-c Chemical
An independent editorial readout of the published MOTS-c research — what the studies measured, and where the evidence stops.
What This Project Is
MOTS-c Chemical is an independent editorial project that publishes summaries of the peer-reviewed research literature on MOTS-c, the 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The approach is deliberately instrument-like: we treat the MOTS-c literature the way a console treats a telemetry channel. Each study is logged with its dose, species, route, and outcome, and tied to a citation a reader can verify. Where a finding is well established — the folate-cycle/AMPK mechanism [1], the nuclear-translocation result [3], the exercise-capacity data [2] — we say so plainly. Where the human evidence stops, we mark the gap rather than fill it.
What the Name Means
The word "chemical" in our domain is editorial framing, not a claim about services. MOTS-c is a research chemical, and this site reads its record as such. We do not occupy the position of a pharmacy, a supplier, or a prescriber: the modifier signals the register of the writing — sober, sourced, evidence-first — not an offer to provide, sell, or supply anything. Nothing on this site is dispensed, priced, or for sale.
We maintain a clear line between two things that are easy to blur: what the science shows and what the marketplace claims. Consumer interest in MOTS-c for fat loss, longevity, and performance runs well ahead of the clinical evidence, which remains observational in humans and interventional only in animals [4][10]. This digest exists to hold those apart.
How We Handle Sources
Every quantitative claim on this site resolves to a numbered reference: a peer-reviewed study via PubMed and DOI, or an audited FDA page for the regulatory readout. We rely on primary literature — Cell Metabolism, Nature Communications, iScience, and the major reviews — rather than secondary commentary, and we cite FDA directly for the MOTS-c legal status and FDA 503A category page. We do not assert future regulatory outcomes as fact, and we present regulatory information as general background, not legal advice. The full source list lives on the MOTS-c references and citations page.